Aktieanalys

Mendus: Adjusting our estimates for ilixadencel - Redeye

{newsItem.title}

Redeye Publicerad: 02 Jan 07:08

Redeye adjusts its estimates after Institut Bergonié terminated the collaboration agreement to explore ilixadencel combination therapy as part of the REGOMUNE trial.

Länk till analysen i sin helhet: https://www.redeye.se/research/1066387/mendus-adjusting-our-estimates-for-ilixadencel?utm_source=finwire&utm_medium=RSS

Nyheter om Mendus

Läses av andra just nu

Om aktien Mendus

Senaste nytt